Schizophrenia Research
Volume 78, Issue 2 , Pages 161-169 , 15 October 2005

Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

  • Stephen M. Strakowski

      Affiliations

    • Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way (ML0583), Cincinnati, OH 45267-0583, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 513 558 2958; fax: +1 513 558 7164.
    • ,
  • Jacqueline L. Johnson

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • ,
  • Melissa P. DelBello

      Affiliations

    • Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way (ML0583), Cincinnati, OH 45267-0583, USA
    • ,
  • Robert M. Hamer

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • ,
  • Alan I. Green

      Affiliations

    • Dartmouth Medical School, Lebanon, NH, USA
    • ,
  • Mauricio Tohen

      Affiliations

    • Eli Lilly and Co., Lilly Research Laboratories, Indianapolis, IN, USA
    • McLean Hospital, Harvard Medical School, Belmont, MA, USA
    • ,
  • Jeffrey A. Lieberman

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • Columbia University, School of Medicine, New York, NY, USA
    • ,
  • Ira Glick

      Affiliations

    • Stanford University School of Medicine, CA, USA
    • ,
  • Jayendra K. Patel

      Affiliations

    • University of Massachusetts Medical Center, MA, USA
    • ,
  • HGDH Research Group

      Affiliations

    • This paper was based in part on results from the study of the Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis by the HGDH Study Group sponsored by Eli Lilly and Company. The HGDH research group consists of Drs. Jeffrey Lieberman and Diana Perkins, Dept. of Psychiatry, Univ. of North Carolina School of Medicine, NC, USA; Drs. Joseph P. McEvoy, Cecil Charles and Richard Keefe, John Ulmstead Hospital, Duke University Health System, NC, USA; Drs. Robert B. Zipursky and Zafiris J. Daskalakis, Dept. of Psychiatry, University of Toronto School of Medicine, Ontario, Canada; Dr. Alan I. Green, Massachusetts Mental Health Center, Harvard Medical School, MA, USA; Dr. Charles B. Nemeroff, Dept. of Psychiatry, Emory University School of Medicine, GA, USA; Prof. Robin Murray and Dr. Tonmoy Sharma, Institute of Psychiatry, UK; Dr. Raquel E. Gur, Dept of Psychiatry, Univ. of Pennsylvania Medical Center, PA, USA; Drs. Bruce Cohen and Franca Centorrino, McLean Hospital, Harvard Medical School, Belmont, MA, USA; Prof. Dr. R.S. Kahn, University Hospital, Utrecht, The Netherlands; Drs. Wayne Goodman and John Kuldau, Dept. of Psychiatry, Univ. of Florida, FL, USA; Drs. Anthony J. Rothschild and Jayendra K. Patel, Dept. of Psychiatry, Univ. of Massachusetts Medical Center, MA, USA; Dr. Stephen M. Strakowski, Dept. of Psychiatry, Univ. of Cincinnati, OH, USA; Dr. Ira Glick, Dept. of Psychiatry, Stanford University School of Medicine, CA, USA; Dr. John De Quardo, Dept. of Psychiatry, Univ. of Michigan Medical Center, MI, USA; Drs. Gary Tollefson, Todd Sanger, Mauricio Tohen, Lilly Research Laboratories, IN, USA.

Received 12 January 2005 ,Revised 13 April 2005 ,Accepted 15 April 2005.

References 

  1. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability — are patients better off?. Canadian Journal of Psychiatry. 2004;49:283–284
  2. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin. 1982;8:470–484
  3. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Editions (SCID-I/P). 722 West 168th Street, New York, NY 10032: Biometrics Research Department, New York State Psychiatric Institute; 1995;
  4. Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research. 2004;66:125–135
  5. Gureje O, Miles W, Keks N, et al. Olanzapine vs. risperidone I the management of schizophrenia: randomized double-blind trial in Australia and New Zealand. Schizophrenia Research. 2003;61:303–314
  6. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276
  7. Kilian R, Dietrich S, Toumi M, Angermeyer MC. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psychiatrica Scandinavica. 2004;110:108–118
  8. Lieberman JA, Sheitman B, Chakos M, et al. The development of treatment resistance in patients with schizophrenia: a clnical and pathophysiological perspective. Journal of Clinical Psychopharmacology. 1998;18:205–245
  9. Lieberman J, Tohen M, Green AI, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized double-blind trial of olanzapine vs. haloperidol. American Journal of Psychiatry. 2003;160:1396–1404
  10. Meijer CJ, Schene AH, Koeter MW. Quality of life in schizophrenia measured by the MOS SF-36 and lancashire quality of life profile: a comparison. Acta Psychiatrica Scandinavica. 2002;105:293–300
  11. Moller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs. 2003;17:793–823
  12. Naber D, Riedel M, Klimke A, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatrica Scandinavica. 2005;111:106–115
  13. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Journal of Clinical Psychiatry. 2004;65:531–536
  14. Perkins, D.O., Johnson, J.L., Hamer, R.M., et al., submitted for publication. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
  15. Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. British Journal of Psychiatry. 2004;185:18–24
  16. Pukrop R, Schlaak V, Möller-Leimkühler AM, et al. Reliability and validity of quality of life assessed by the short-form 36 and the modular system for quality of life in patients with schizophrenia and patients with depression. Psychiatry Research. 2003;119:63–79
  17. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Quality of Life Research. 1999;8:417–426
  18. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. Journal of Clinical Psychopharmacology. 2004;24:582–591
  19. Rosenheck R, Perlick D, Bingham D, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Journal of the American Medical Association. 2003;290:2693–2702
  20. Russo J, Trujillo CA, Wingerson D, et al. The MOS 36-item short form healthy survey: reliability, validity and preliminary findings in schizophrenic outpatients. Medical Care. 1998;36:752–756
  21. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatric Clinics of North America. 2003;26:25–40
  22. Strakowski SM. Diagnostic validity of schizophreniform disorder. American Journal of Psychiatry. 1994;151:815–824
  23. Tunis SL, Croghan TW, Heliman DK, Johnstone BM, Obenchain RL. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Medical Care. 1999;37:678–691
  24. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993;
  25. Ware JE, Koskinsk M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, New England Medical Center; 1994;

PII: S0920-9964(05)00168-4

doi: 10.1016/j.schres.2005.04.017

Schizophrenia Research
Volume 78, Issue 2 , Pages 161-169 , 15 October 2005

Article Tools

* Image Usage & Resolution